All data are based on the daily closing price as of September 1, 2025
a

Astellas Pharma

4503.TSE
11.18 USD
0.16
+1.45%

Overview

Last close
11.18 usd
Market cap
20.01B usd
52 week high
12.40 usd
52 week low
8.65 usd
Target price
11.51 usd

Valuation

P/E
57.4672
Forward P/E
12.3457
Price/Sales
1.4912
Price/Book Value
1.9573
Enterprise Value
24.05B usd
EV/Revenue
1.8494
EV/EBITDA
14.2577

Key financials

Revenue TTM
13.23B usd
Gross Profit TTM
10.83B usd
EBITDA TTM
3.30B usd
Earnings per Share
0.19 usd
Dividend
0.5 usd
Total assets
22.40B usd
Net debt
4.31B usd

About

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemia associated with chronic kidney disease (CKD); Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. The company has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Chuo, Japan.
  • Symbol
    4503.TSE
  • Exchange
    TSE
  • Isin
    JP3942400007
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Mr. Naoki Okamura BSc
  • Headquarter
    Chuo
  • Web site
    https://www.astellas.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top